TW202330458A - 用於遞送的脂質和組成物 - Google Patents

用於遞送的脂質和組成物 Download PDF

Info

Publication number
TW202330458A
TW202330458A TW111150722A TW111150722A TW202330458A TW 202330458 A TW202330458 A TW 202330458A TW 111150722 A TW111150722 A TW 111150722A TW 111150722 A TW111150722 A TW 111150722A TW 202330458 A TW202330458 A TW 202330458A
Authority
TW
Taiwan
Prior art keywords
compound
salt
extended
alkyl
alkenyl
Prior art date
Application number
TW111150722A
Other languages
English (en)
Chinese (zh)
Inventor
祝令建
石健宇
劉崇懿
姜軍
黃建
Original Assignee
大陸商江蘇恆瑞醫藥股份有限公司
大陸商上海森輝醫藥有限公司
大陸商上海盛迪醫藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商江蘇恆瑞醫藥股份有限公司, 大陸商上海森輝醫藥有限公司, 大陸商上海盛迪醫藥有限公司 filed Critical 大陸商江蘇恆瑞醫藥股份有限公司
Publication of TW202330458A publication Critical patent/TW202330458A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW111150722A 2021-12-29 2022-12-29 用於遞送的脂質和組成物 TW202330458A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202111638123.4 2021-12-29
CN202111638123 2021-12-29
CN202210651178.7 2022-06-09
CN202210651178 2022-06-09

Publications (1)

Publication Number Publication Date
TW202330458A true TW202330458A (zh) 2023-08-01

Family

ID=86998079

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111150722A TW202330458A (zh) 2021-12-29 2022-12-29 用於遞送的脂質和組成物

Country Status (10)

Country Link
US (1) US20250064750A1 (enExample)
EP (1) EP4458806A4 (enExample)
JP (1) JP2025501967A (enExample)
KR (1) KR20240128984A (enExample)
CN (1) CN120476106A (enExample)
AU (1) AU2022424144A1 (enExample)
CA (1) CA3242974A1 (enExample)
MX (1) MX2024007242A (enExample)
TW (1) TW202330458A (enExample)
WO (1) WO2023125738A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023343844A1 (en) * 2022-09-19 2025-04-10 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Method for preparing 2-hydroxyethyl aminocaproate compound and use thereof
AU2024307171A1 (en) 2023-06-28 2026-01-15 Shanghai Regenelead Therapies Co., Ltd. Pharmaceutical composition containing cationic lipid and use thereof
WO2025103396A1 (zh) * 2023-11-14 2025-05-22 上海瑞宏迪医药有限公司 一种含核酸构建体的药物组合物及其医药用途
WO2025103414A1 (zh) * 2023-11-14 2025-05-22 上海瑞宏迪医药有限公司 一种脂质纳米粒的制备方法和应用
TW202532053A (zh) * 2023-12-13 2025-08-16 大陸商上海瑞宏迪醫藥有限公司 用於遞送治療劑的組成物和化合物
CN119019272A (zh) * 2024-08-14 2024-11-26 中国药科大学 可电离脂质、包含其的组合物及其用途
CN119191996A (zh) * 2024-11-28 2024-12-27 浙江省质量科学研究院 一种双羟乙基氨基丙基羟乙基油胺的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS63030B1 (sr) 2015-09-17 2022-04-29 Modernatx Inc Jedinjenja i kompozicije za intracelularno isporučivanje terapeutskih sredstava
RS63986B1 (sr) * 2015-10-28 2023-03-31 Acuitas Therapeutics Inc Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
BR112021021313A2 (pt) 2019-04-25 2022-01-18 Intellia Therapeutics Inc Lipídios de amina ionizáveis e nanopartículas de lipídio
CN114763324A (zh) * 2021-01-15 2022-07-19 纳肽得(青岛)生物医药有限公司 一种脂质化合物及脂质体与药物组合物
CN113264842B (zh) * 2021-07-21 2022-03-01 苏州科锐迈德生物医药科技有限公司 一种脂质化合物及包含其的脂质载体、核酸脂质纳米粒组合物和药物制剂
CN114773217B (zh) * 2022-06-20 2022-10-18 深圳市瑞吉生物科技有限公司 用于递送核酸的阳离子脂质化合物和组合物及用途

Also Published As

Publication number Publication date
MX2024007242A (es) 2024-06-26
JP2025501967A (ja) 2025-01-24
WO2023125738A1 (zh) 2023-07-06
CN120476106A (zh) 2025-08-12
CA3242974A1 (en) 2023-07-06
EP4458806A4 (en) 2025-04-30
AU2022424144A1 (en) 2024-08-08
EP4458806A1 (en) 2024-11-06
US20250064750A1 (en) 2025-02-27
KR20240128984A (ko) 2024-08-27

Similar Documents

Publication Publication Date Title
WO2023125738A1 (zh) 用于递送的脂质和组合物
US11713317B2 (en) Tricyclic heterocyclic compounds as sting activators
JP7410135B2 (ja) 治療薬の細胞内送達のための化合物及び組成物
AU2017356699A1 (en) Cationic lipids for nucleic acid delivery and preparation thereof
WO2024107906A2 (en) Ionizable lipids and lipid nanoparticle compositions for the delivery of nucleic acids
TW202302525A (zh) 苯醯胺類化合物及其用途
CN117924106B (zh) 可电离脂质化合物
CN120752027A (zh) 编码治疗性多肽的核酸及包含所述核酸的脂质纳米颗粒组合物
CN115490610A (zh) 苯-1,3,5-三甲酰胺衍生物及其用途
CN116970027A (zh) 哑铃型两亲性肽类树形分子、合成及其作为药物递送系统的应用
WO2025124548A1 (zh) 一种咪唑类脂质及其应用
WO2025124541A1 (zh) 一种阳离子脂质及其应用
US12233161B1 (en) Lipids and lipid nanoparticle formulations
US12599560B2 (en) Lipids and lipid nanoparticle formulations
CN116396358B (zh) 一种骨靶向纳米脂质颗粒的制备及应用
ES2969594T3 (es) Complejo de 7-desacetilforskolina y PVP
US20240245617A1 (en) Lipid-based topical injection formulations
CN122028908A (zh) 用于递送治疗剂的组合物和化合物
WO2025209467A1 (en) Lipids and lipid nanoparticle formulations
CN120058545A (zh) 一类氨基醇类脂质分子的制备与应用
JP2019038778A (ja) ホウ素含有葉酸誘導体
US20250312288A1 (en) Lipids and lipid nanoparticle formulations
TWI686392B (zh) 含有乙內醯脲衍生物之醫藥組合物
JP2025514198A (ja) 二重機能免疫調節化合物、製剤、及びその使用
CN119896673A (zh) Glp-1r激动剂与二甲双胍在制备治疗糖尿病及其并发症药物中的应用